Reverse phase HPLC for polar lipids. Simple and selective HPLC procedures for analysis of phospholipid-based derivatives of valproic acid and various non-steroidal anti-inflammatory drugs

被引：21

作者：

Ioffe, V ^{[1
]}

Kalendarev, T ^{[1
]}

Rubinstein, I ^{[1
]}

Zupkovitz, G ^{[1
]}

机构：

[1] D Pharm Ltd, Kiryat Weizmann Sci Pk, IL-76123 Rehovot, Israel

来源：

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 2002年 / 30卷 / 03期

关键词：

HPLC; reverse phase; valproic acid; phospholipids; anti-epileptic drugs; non-steroidal anti-inflammatory drug; stability-indicating method; bioanalysis;

D O I：

10.1016/S0731-7085(02)00220-0

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

DP-VPA (SPD 421)(1) is a new compound, where valproic acid is chemically bound to lecithin. It is a novel prodrug of valproic acid with targeted action for the treatment of epilepsy. RP-HPLC stability indicating method has been developed for this and relative compounds. Versatile detection techniques could be used with these LC procedures. The absence of non-volatile components in the mobile phase allows running the method with evaporative light scattering and MS-detectors. The method appeared to be sensitive, selective, reproducible, and stability indicating. It could be easily upgraded to bioanalytical procedures applying LC-MS technique. The method could be used as 'generic' for numerous compounds having similar design of the molecules, such as lecithin-based derivatives of diclofenac, naproxen, ibuprofen, and indometacin. The strategy of HPLC method development for polar lipids is discussed. (C) 2002 Elsevier Science B.V. All rights reserved.

引用

页码：391 / 403

页数：13

共 9 条

[1]

*FDA, 2000, GUID IND AN PROC MET

[2]

*ICH, 1997, Q2B IHC

[3]

JAIN KK, 2000, EXPERT OPIN INV DRUG, V9, P840

[4]

KUSTY RL, 1999, EPILEPSIA, V40, P266

[5]

NEI M, 1999, EPILEPSIA, V40, P163

[6]

SHIBAMOTO T, 1994, CHROMATOGRAPHIC SCI, V65, P412

[7]

TYMAN JHP, 1994, DEV ANAL LIPIDS, P206

[8]

0031083

[9]

6166089

← 1 →